Seth A Rosenthal
Overview
Explore the profile of Seth A Rosenthal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
3563
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel K, Nguyen P, Proudfoot J, Liu Y, Dal Pra A, Spratt D, et al.
Eur Urol Oncol
. 2024 Nov;
PMID: 39542826
Background And Objective: Long-term (LT) androgen deprivation therapy (ADT) has been found to be beneficial to patients with high-risk prostate cancer (PCa). However, administration of LT-ADT to all patients with...
2.
Sartor O, Karrison T, Sandler H, Gomella L, Amin M, Purdy J, et al.
Eur Urol
. 2024 Jun;
86(3):289-290.
PMID: 38897867
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of...
3.
Lee S, Goldberg M, Rosenthal S, Maibach E, Kotcher J, Leiserowitz A
PLoS One
. 2024 Mar;
19(3):e0300048.
PMID: 38507396
Beliefs and attitudes form the core of public opinion about climate change. Network analysis can reveal the structural configuration of these beliefs and attitudes. In this research, we utilize a...
4.
Mak K, Scannell Bryan M, Dignam J, Shipley W, Lin Y, Peters C, et al.
Eur Urol Focus
. 2024 Feb;
10(2):271-278.
PMID: 38307806
Background: Androgen deprivation therapy (ADT) has been associated with coronary heart disease and myocardial infarction (MI) in prostate cancer patients, but controversy persists regarding its effects on cardiovascular mortality (CVM)....
5.
Ross A, Zhang J, Huang H, Yamashita R, Keim-Malpass J, Simko J, et al.
Eur Urol Oncol
. 2024 Feb;
7(5):1024-1033.
PMID: 38302323
Background: Accurate risk stratification is critical to guide management decisions in localized prostate cancer (PCa). Previously, we had developed and validated a multimodal artificial intelligence (MMAI) model generated from digital...
6.
Amini A, Luh J, Bush A, Rosenthal S
J Am Coll Radiol
. 2024 Feb;
21(7):1141-1144.
PMID: 38302043
Since 2017, the specialty of radiation oncology has experienced its fifth consecutive year of decline in residency applicants, resulting in a high number of unmatched positions. The cause of this...
7.
Michalski J, Winter K, Prestidge B, Sanda M, Amin M, Bice W, et al.
J Clin Oncol
. 2023 Jun;
41(24):4035-4044.
PMID: 37315297
Purpose: To determine whether addition of external beam radiation therapy (EBRT) to brachytherapy (BT) (COMBO) compared with BT alone would improve 5-year freedom from progression (FFP) in intermediate-risk prostate cancer....
8.
Akin O, Woo S, Oto A, Allen B, Avery R, Barker S, et al.
J Am Coll Radiol
. 2023 May;
20(5S):S187-S210.
PMID: 37236742
Prostate cancer is second leading cause of death from malignancy after lung cancer in American men. The primary goal during pretreatment evaluation of prostate cancer is disease detection, localization, establishing...
9.
Turkbey B, Oto A, Allen B, Akin O, Alexander L, Ari M, et al.
J Am Coll Radiol
. 2023 May;
20(5S):S164-S186.
PMID: 37236741
Prostate cancer has a wide spectrum ranging between low-grade localized disease and castrate-resistant metastatic disease. Although whole gland and systematic therapies result in cure in the majority of patients, recurrent...
10.
Sartor O, Karrison T, Sandler H, Gomella L, Amin M, Purdy J, et al.
Eur Urol
. 2023 May;
84(2):156-163.
PMID: 37179241
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of...